{"id":"NCT03954834","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone","officialTitle":"A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-03","primaryCompletion":"2020-10-05","completion":"2020-10-28","firstPosted":"2019-05-17","resultsPosted":"2021-10-20","lastUpdate":"2021-10-20"},"enrollment":478,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Tirzepatide","otherNames":["LY3298176"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"5 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"10 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"15 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone. The study will last approximately 47 weeks and may include about 15 visits.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c)","timeFrame":"Baseline, Week 40","effectByArm":[{"arm":"5 mg Tirzepatide","deltaMin":-1.87,"sd":0.094},{"arm":"10 mg Tirzepatide","deltaMin":-1.89,"sd":0.096},{"arm":"15 mg Tirzepatide","deltaMin":-2.07,"sd":0.098},{"arm":"Placebo","deltaMin":0.04,"sd":0.105}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG001 vs OG003","p":"<0.001"},{"comp":"OG002 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":53,"countries":["United States","India","Japan","Mexico","Puerto Rico"]},"refs":{"pmids":["39531161","37668888","37526908","35210595","34186022"],"seeAlso":["https://www.lillytrialguide.com/en-US/studies/adult-type-2-diabetes/GPGK#?postal="]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":121},"commonTop":["Nausea","Diarrhoea","Hyperglycaemia","Nasopharyngitis","Dyspepsia"]}}